Intangible Assets and Royalty Agreement (Details) (USD $)	0 Months Ended		9 Months Ended		12 Months Ended	3 Months Ended				3 Months Ended				3 Months Ended				3 Months Ended				3 Months Ended				3 Months Ended				3 Months Ended				3 Months Ended				3 Months Ended				3 Months Ended				3 Months Ended
	Mar. 31, 2008	Jan. 29, 2007	Sep. 30, 2013		Dec. 31, 2012	Sep. 30, 2013 Trade Names and Trademarks [Member]		Dec. 31, 2012 Trade Names and Trademarks [Member]		Sep. 30, 2013 In Process Research and Development, Other [Member]		Dec. 31, 2012 In Process Research and Development, Other [Member]		Sep. 30, 2013 Patents in Process [Member]		Dec. 31, 2012 Patents in Process [Member]		Sep. 30, 2013 License-Shriners Hsp for Children & USF Research [Member]		Dec. 31, 2012 License-Shriners Hsp for Children & USF Research [Member]		Sep. 30, 2013 License - SaluMedica LLC Spine Repair [Member]		Dec. 31, 2012 License - SaluMedica LLC Spine Repair [Member]		Sep. 30, 2013 License - Polyvinyl Alcohol Cryogel [Member]		Dec. 31, 2012 License - Polyvinyl Alcohol Cryogel [Member]		Sep. 30, 2013 Customer Relationships [Member]		Dec. 31, 2012 Customer Relationships [Member]		Sep. 30, 2013 Supplier Relationships [Member]		Dec. 31, 2012 Supplier Relationships [Member]		Sep. 30, 2013 Patents and Know-How [Member]		Dec. 31, 2012 Patents and Know-How [Member]		Sep. 30, 2013 Micronized Processing Know-How [Member]		Dec. 31, 2012 Micronized Processing Know-How [Member]		Sep. 30, 2013 Licenses and Permits [Member]		Dec. 31, 2012 Licenses and Permits [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives																		10 years	[1]			10 years	[2]			10 years	[3]			14 years	[4]			14 years	[4]			17 years	[4]			14 years	[4]			3 years	[4]
Gross Carrying Value			$ 15,811,682		$ 17,526,000													$ 996,000	[1]	$ 996,000	[1]	$ 1,547,324	[2]	$ 2,399,000	[2]	$ 1,720,181	[3]	$ 2,667,000	[3]	$ 3,520,000	[4]	$ 3,520,000	[4]	$ 241,000	[4]	$ 241,000	[4]	$ 5,614,177	[4]	$ 5,530,000	[4]	$ 2,160,000	[4]	$ 2,160,000	[4]	$ 13,000	[4]	$ 13,000	[4]
Accumulated Amortization			(5,638,565)		(4,848,756)													(662,333)	[1]	(587,633)	[1]	(1,547,324)	[2]	(1,547,324)	[2]	(1,319,956)	[3]	(1,223,561)	[3]	(691,429)	[4]	(502,857)	[4]	(47,339)	[4]	(34,428)	[4]	(1,088,267)	[4]	(790,000)	[4]	(270,000)	[4]	(154,286)	[4]	(11,917)	[4]	(8,667)	[4]
Acquisition price, one-time license fee		100,000
Impairment Adjustment					(1,798,495)																			(851,676)	[2]			(946,819)	[3]
Net carrying value, Total			10,173,117		10,878,749													333,667	[1]	408,367	[1]	0	[2]	0	[2]	400,225	[3]	496,620	[3]	2,828,571	[4]	3,017,143	[4]	193,661	[4]	206,572	[4]	4,525,910	[4]	4,740,000	[4]	1,890,000	[4]	2,005,714	[4]	1,083	[4]	4,333	[4]
Shares issued for intangibles (in shares)		1,120,000
Value of shares issued for intangibles		896,000
Maximum time of approval		30 days
Contingent payments to licensor		200,000
Contingent royalty to be paid to licensor (in hundredths)		3.00%
Acquisition price of asset, shares issued (in shares)	400,000
Acquisition of asset, value of shares issued	2,596,000
Number of shares issuable upon meeting certain milestones (in shares)	600,000
Contingent payments to licensor, shares issued (in shares)	100,000
Contingent payment to licensor, value of shares issued	71,000
Additional accrued obligation			0		0
Indefinite-lived Intangible Assets [Line Items]
Weighted average useful life Indefinite lived						indefinite	[4]			indefinite	[4]			indefinite	[5]
Gross Carrying Value						1,008,000	[4]	1,008,000	[4]	25,000	[4]	25,000	[4]	442,389	[5]	0	[5]
Accumulated Amortization						0	[4]	0	[4]	0	[4]	0	[4]			0	[5]
Net Carrying Value						1,008,000	[4]	1,008,000	[4]	25,000	[4]	25,000	[4]	442,389	[5]	0	[5]
Intangible assets, gross carrying value			16,844,682		18,559,000
Impairment Adjustment					(1,798,495)
Accumulated Amortization			(5,638,565)		(4,848,756)
Intangible assets, net carrying value			11,648,506		11,911,749
Estimated future amortization expense [Abstract]
2013			263,833	[6]
2014			1,050,998
2015			1,028,944
2016			981,950
2017			891,753
Thereafter			$ 5,955,639

[1] On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. The acquisition price of this license was a one-time fee of $100,000 and 1,120,000 shares of common stock valued at $896,000 (based upon the estimated fair value of the common stock on the transaction date). Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products

[2] License from SaluMedica, LLC (SaluMedica) for the use of certain developed technologies related to spine repair. This license was acquired through the acquisition of SpineMedica Corp. In September 2012, the cost of this license was deemed to be impaired and reduced to its fair value

[3] On March 31, 2008, the Company entered into a license agreement for the use of certain developed technologies related to surgical sheets made of polyvinyl alcohol hydrogel. The acquisition price of the asset was 400,000 shares of common stock valued at $2,596,000 (based upon the closing price of the common stock on the transaction date). The agreement also provides for the issuance of an additional 600,000 shares upon the Company meeting certain milestones related to future sales. On December 31, 2009, the Company completed the sale of its first commercial product and met its first milestone under this agreement. As a result, the Company issued an additional 100,000 shares of common stock to the licensor valued at $71,000. In September 2012, the cost of the license was deemed to be impaired and reduced to its fair value. At September 30, 2013, and December 31, 2012, there are no additional amounts accrued for this obligation due to its contingent nature

[4] On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for customer and supplier relationships, patents and know-how, licenses/permits, trade names and trademarks and in-process research and development

[5] Capitalized external legal and other registration costs in connection with internally developed tissue based patents that are pending issuance. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization

[6] )Estimated amortization expense for the year ending December 31, 2013 includes only amortization to be recorded after September 30, 2013.